The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy

Circulation

Volumn 114, Issue 22, 2006, Pages 2313-2316

  Mahaffey, Kenneth W ^a   Becker, Richard C ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; FONDAPARINUX; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PREKALLIKREIN; REAGENT; RIVAROXABAN; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CATHETER THROMBOSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; EXPERIMENTAL MODEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; STANDARDIZATION; THROMBOSIS; TOTAL HIP PROSTHESIS; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOUBLE-BLIND METHOD; FACTOR XA; HUMANS; MORPHOLINES; POSTOPERATIVE PERIOD; THIOPHENES;

EID: 33751581208     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.664169     Document Type: Editorial

References (25)

1. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature (Lond). 1954;202:498-499.
2. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310-1312.
3. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006;26:41-49.
4. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost. 2006;32:32-38.
5. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis. 2006;36:108-117.
6. Potti A, Bild A, Dressman HK, Lews DA, Nevins JR, Ortel TL. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood. 2006;107:1391-1396.
7. Graham JB. Stuart Factor: discovery and designation as factor X. Thromb Haemost. 2003;1:871-877.
8. Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in health volunteers. Thromb Res. 1996;81:533-543.
9. Bouchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem. 1997;272:9244-9251.
10. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost. 2001;86:8-13.
11. Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDeominicis G, and Altieri DC. Factor Xa as interface between coagulation and inflammation: molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest. 1997;99:2446-2451.
12. Daubie V, Cauwenberghs S, Senden HN, Pochet R, Lindhout T, Buurman WA, Heemskerk JW. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta. 2006;8:860-869.
13. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):338S-400S.
14. Bauersachs RM. Fondaparinux: an update on new study results. Eur J Clin Invest. 2005;35:27-32.
15. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, for the ODIXa-HIP Study Investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.
16. Eikelboom JW, Mehta SR, Anand SS, Changchun X, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
17. Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis. 2006;21:167-174.
18. Lehman CM, Reggmann Ja, Wilson LW, Marketwitz BA. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol. 2006;126:416-421.
19. Dyke CK, Becker RC, Kleiman NS, Hochamn JS, Bovill EG, Lincoff MA, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson T, Kunitado S, Armstrong PW, Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamics evaluation. Circulation. 2002;105:2382-2388.
20. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics and pharmacokinetics of single dosese of BAY59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther.. 2005;78:412-421.
21. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators(OASIS-5). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
22. The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. JAMA. 2006;295:1519-1530.
23. a, and kallikrein by antithrombin. Biochem J. 1981;193:395-400.
24. Rosenberg RD. Chemistry of the haemostatic mechanism and its relationship to the action of heparin. Fed Proc. 1977;36:10.
25. Huang L. Kerns RJ. Diversity-oriented chemical modification of heparin: identification of charge-reduced N-acyl heparin derivatives having increased selectivity for heparin-binding proteins. Bioorg Med Chem. 2006;14:2300-2313.